NYSE:CPHI
CHINA PHARMA HOLDINGS, INC.
A mid-cap biopharmaceutical firm navigating revenue contraction while maintaining a strategic asset base for potential pipeline expansion.
Key Metrics
Investment Thesis
Bull Case
Attractive valuation metrics relative to peers suggest potential for turnaround value if management can stabilize the revenue decline, while significant non-cash adjustments and asset holdings provide a buffer for strategic restructuring or M&A activity.
Bear Case
Consistent negative operating cash flow and widening losses over the last three years signal fundamental business deterioration that may deter institutional investors without clear catalysts for growth or profitability improvement.
About CHINA PHARMA HOLDINGS, INC.
China Pharma Holdings Inc. (CPHI) operates as a diversified pharmaceutical entity focusing on drug distribution, generic manufacturing, and specialized R&D initiatives primarily serving the North American and Asian markets.
Analysis
Management Discussion
The company reported a net loss of $4.7M in 2024 alongside a sharp decline in total revenue from $8.1M in 2022 to $4.5M, reflecting challenging market conditions and operational inefficiencies that have depleted cash reserves by nearly $800K year-over-year.
Industry Overview
The pharmaceutical sector is currently characterized by intense competition among generic manufacturers, strict regulatory oversight on drug pricing, and a transitional shift from traditional generics to biosimilars and novel therapies.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $8.1M | $7.0M | $4.5M |
| Cost of Revenue | $8.6M | $7.3M | $6.5M |
| Gross Profit | $-493.9K | $-281.1K | $-2.0M |
| Operating Expenses | $3.1M | $2.5M | $2.6M |
| Operating Income | $-3.5M | $-2.8M | $-4.6M |
| R&D | $185.9K | $240.1K | $283.9K |
| G&A | $1.9M | $1.5M | $1.8M |
| D&A | $2.7M | $2.8M | $2.6M |
| Depreciation | $2.7M | $2.5M | $2.2M |
| Amortization | $36.6K | $223.8K | $447.2K |
| Other OpEx | $975.9K | $764.6K | $534.5K |
| Non-Operating Income | $-423.9K | $-327.0K | $-147.5K |
| Interest Expense | $434.6K | $333.6K | $27.4K |
| Interest Income | $10.8K | $6.6K | $6.6K |
| Pre-Tax Income | $-4.0M | $-3.1M | $-4.7M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-4.0M | $-3.1M | $-4.7M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-4.0M | $-3.1M | $-4.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-4.0M | $-3.1M | $-4.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $6.0M | $6.0M | $3.3M |
| Cash & Equivalents | $2.0M | $1.4M | $600.0K |
| Accounts Receivable | — | $504.4K | $232.1K |
| Inventory | $2.9M | $3.7M | $2.3M |
| Other Current Assets | $986.8K | $336.1K | $172.1K |
| Long-Term Assets | $11.8M | $10.5M | $11.6M |
| PP&E (Net) | $10.0M | $7.1M | $4.9M |
| Intangibles | $1.8M | $3.3M | $6.7M |
| Operating Leases | $39.0K | $116.6K | $38.3K |
| Other LT Assets | $0 | $0 | $0 |
| Total Assets | $17.8M | $16.5M | $14.9M |
| Current Liabilities | $12.7M | $6.8M | $5.0M |
| Current Leases | $40.4K | $77.7K | $39.3K |
| Deferred Revenue | $520.3K | $90.5K | $162.2K |
| Other Current Liab | $11.8M | $6.4M | $4.6M |
| Long-Term Liabilities | $754.7K | $2.2M | $2.1M |
| LT Operating Leases | — | $39.9K | — |
| Other LT Liab | $-1.7M | $1.1M | $1.1M |
| Total Liabilities | $13.5M | $9.0M | $7.1M |
| Shareholders' Equity | $4.3M | $7.5M | $7.7M |
| Paid-In Capital | $28.9M | $35.3M | $40.6M |
| Retained Earnings | $-36.2M | $-39.3M | $-44.0M |
| AOCI | $11.6M | $11.5M | $11.3M |
| Total L&E | $17.8M | $16.5M | $14.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-4.0M | $-3.1M | $-4.7M |
| Non-Cash Adjustments | $3.2M | $1.7M | $5.9M |
| Working Capital Changes | $349.9K | $697.3K | $-1.7M |
| Cash from Operations | $-409.5K | $-699.7K | $-466.4K |
| Capital Expenditures | $402.0K | — | $38.4K |
| Cash from Investing | $-402.0K | $-11.5K | $-291.7K |
| Cash from Financing | $-1.8M | $73.1K | $27.4K |
| FX Effect | $-247.6K | $31.9K | $-66.2K |
| Net Change in Cash | $-2.8M | $-606.1K | $-797.0K |
| Beginning Cash | $4.9M | $2.0M | $1.4M |
| Ending Cash | $2.0M | $1.4M | $626.9K |
Frequently Asked Questions
How does CHINA PHARMA HOLDINGS, INC. make money?
The company derives revenue from generic drug sales and wholesale distribution channels, supplemented by research and development activities for proprietary formulations and contract manufacturing services.
What are the main risks for CPHI?
Significant cash burn from operations coupled with declining revenue trends raises sustainability concerns, heavy reliance on generic drug margins exposes the firm to pricing pressure, and substantial retained earnings deficits indicate potential solvency stress.
What is CPHI's competitive advantage?
Leverages an extensive existing supply chain network to maintain logistical efficiency, utilizes a portfolio of patent-expired generics to capture market share, and maintains flexible capital structures to navigate regulatory shifts.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.